CD79A and COVID-19: 3.5. Mucosal IgA Generated Against SARS-CoV-2 Omicron Infection Leading to Enhanced, Effective, and Cross Neutralization Against BA.1, BA.2, and BA.5 from Nasal Swab Samples of Triple Vaccinated and SARS-CoV-2 Infected Individuals